BSD Medical Reports News Briefing at Europe's Largest Cancer Congress: Hyperthermia and Chemotherapy Treatment Prolongs Survival of Sarcoma Cancer Patients

The press information stated that, "The study, which found that the addition of the innovative heat technique more than doubled the proportion of patients whose tumours responded to chemotherapy without increasing toxicity, is also the first to show that any treatment other than surgery followed by radiation can prolong survival of this type of patient." The press release also stated that the results increase the case for intensifying the exploration of this type of treatment of other types of cancer. "These findings provide a new standard treatment option, and we believe they are likely to change the way many specialists treat these tumours," said the study's leader, Professor Rolf Issels, a professor of medical oncology at Klinikum Grosshadern Medical Center at the University of Munich in Germany, who presented the results at the ECCO-ESMO congress.

"But the implications of these findings are more far-reaching," Prof. Issels said. "This is also the first clear evidence that targeted heat therapy adds to chemotherapy. We expect our findings will encourage other researchers to test the approach in other locally advanced cancers. Targeted heat therapy has already shown promise in recurrent breast and locally advanced cervical cancer in combination with radiation and studies; combining it with chemotherapy in other localised tumours such as those in the pancreas and rectum are ongoing."

The Phase III study involved 341 patients who were treated at medical centers in Europe and in the United States. All patients had locally advanced soft tissue sarcomas and were at high risk of recurrence and spread. All patients were given chemotherapy before and after surgery and radiotherapy. Half of the patients were randomly given hyperthermia along with chemotherapy.

"The patients receiving the targeted heat therapy fared better on all outcome measurements," Prof. Issels said. "Almost three years after starting treatment, they were 42% less likely to experience a recurrence of their cancer at the same site or to die than those who were getting chemotherapy alone, surviving an estimated 120 months before local progression of their disease, compared with an estimated 75 months. Similarly, the average length of time that patients remained disease free was 32 months in the group that got both treatments, compared with 18 months in the group that got chemotherapy alone -- an improvement of 30%."

About ECCO - ESMO

ECCO15 -- ESMO34 is the Joint 15th Congress of the European CanCer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO). The co-branded multidisciplinary meeting is held every two years. The ECCO-ESMO press information, including press contact information, has been provided in its entirety at: http://www.ecco-org.eu/page.aspx/1671 and at http://bsdmc.com/pdf/ECCO-ESMO_Sarcoma_Press_Release.pdf.

About BSD Medical

BSD Medical's product line includes systems that have been strategically designed to offer a range of thermal treatment systems. The BSD-2000 Hyperthermia System is under investigational device restrictions in the U.S. For further information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

SOURCE: BSD Medical Corporation

BSD Medical Corporation, Salt Lake City 
Dennis Gauger, 801-972-5555 
Fax: 801-972-5930 
investor@bsdmc.com